US equities
|
SPCX
$166.91
▲+5.00%
NVDA
$236.87
▲+1.25%
MU
$1,064.14
▼-1.00%
TSLA
$377.26
▲+1.80%
MSFT
$526.47
▲+1.73%
SNDK
$1,712.13
▼-0.46%
INTC
$117.36
▼-1.65%
META
$744.76
▲+2.29%
SPCX
$166.91
▲+5.00%
NVDA
$236.87
▲+1.25%
MU
$1,064.14
▼-1.00%
TSLA
$377.26
▲+1.80%
MSFT
$526.47
▲+1.73%
SNDK
$1,712.13
▼-0.46%
INTC
$117.36
▼-1.65%
META
$744.76
▲+2.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sanofi - American Depositary Shares
(NQ:
SNY
)
39.33
-0.59 (-1.49%)
Delayed Quote
Updated: 11:58 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
42
43
Next >
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
↗
December 15, 2022
Via
Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
↗
December 14, 2022
Business wins are shining the spotlight on these two companies.
Via
The Motley Fool
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
↗
December 14, 2022
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase.
Via
InvestorPlace
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
↗
December 14, 2022
Via
Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
↗
December 14, 2022
The company is working on protein degradation in cancer and inflammatory diseases.
Via
Investor's Business Daily
Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal
↗
December 12, 2022
HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies.
Via
InvestorPlace
Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal
↗
December 12, 2022
The deal comes a day after Sanofi dropped out of the bidding process.
Via
Investor's Business Daily
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
↗
December 12, 2022
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU
Via
Benzinga
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
↗
December 12, 2022
Via
Benzinga
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
↗
December 09, 2022
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.
Via
The Motley Fool
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
December 09, 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Via
MarketBeat
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
↗
December 08, 2022
Via
Benzinga
This Monster Dividend Stock Isn't Done Growing
↗
December 08, 2022
Is another deal on the way for Johnson & Johnson?
Via
The Motley Fool
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
↗
December 08, 2022
Via
Benzinga
Fusion Fuel (HTOO) Stock Is Up 11% on HUGE Deal News
↗
December 07, 2022
Fusion Fuel (HTOO) stock is heading higher on Wednesday after the company secured a deal with the Portuguese government.
Via
InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
↗
December 07, 2022
TransCode Therapeutics (RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering.
Via
InvestorPlace
SNY Stock Alert: Why 1 Analyst Says Zantac Ruling Is ‘Best-Case Scenario’ for Drugmakers
↗
December 07, 2022
Sanofi (SNY) stock is in the news as one analyst believes the latest court ruling is the "best-case scenario" for the drugmaker.
Via
InvestorPlace
Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07
↗
December 07, 2022
Benzinga
Via
Benzinga
Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac
↗
December 07, 2022
Via
Benzinga
These 3 Stocks Escaped Tuesday's Market Downdraft
↗
December 06, 2022
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Via
The Motley Fool
Why GSK Plc And Sanofi SA Stock Are Shooting Higher
↗
December 06, 2022
Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.
Via
Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06, 2022
From
Singapore Economic Development Board (EDB)A*STAR
Via
ACN Newswire
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
↗
December 05, 2022
There are now two companies in the ring for a Horizon takeover.
Via
Investor's Business Daily
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
↗
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash
↗
December 02, 2022
Via
Benzinga
Why Horizon Therapeutics Stock Is Skyrocketing Today
↗
November 30, 2022
Three big drugmakers could be interested in acquiring Horizon.
Via
The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
↗
November 30, 2022
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout.
Via
InvestorPlace
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
↗
November 30, 2022
Tech layoffs are in the news, but life sciences companies seem to be doing better.
Via
The Motley Fool
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
↗
November 30, 2022
Via
Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
↗
November 30, 2022
Reuters
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
42
43
Next >
